Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lineage Cell Therapeutics Inc. (LCTX:NYSE), powered by AI.
Lineage Cell Therapeutics Inc. is currently trading at $1.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lineage Cell Therapeutics Inc. on Alpha Lenz.
Lineage Cell Therapeutics Inc.'s P/E ratio is -4.3.
“Lineage Cell Therapeutics Inc. trades at a P/E of -4.3 (undervalued) with modest ROE of -103.4%.”
Ask for details →Lineage Cell Therapeutics Inc. is a biotechnology company specializing in the development and commercialization of novel cell therapies. The primary focus of Lineage is to harness the power of cell therapy to treat various degenerative diseases, a sector that is increasingly gaining traction as an alternative to traditional medicines. A notable aspect of the company’s portfolio includes allogeneic, or "off-the-shelf," cell therapies aimed at treating conditions like spinal cord injuries, dry age-related macular degeneration, and cancer. By leveraging its proprietary cell therapy platform, Lineage Cell Therapeutics is at the forefront of regenerative medicine, offering solutions that could potentially transform standard care practices. Within the financial markets, Lineage Cell Therapeutics holds significant importance due to its innovative approach to biotechnology, impacting sectors such as healthcare and pharmaceuticals. The company’s commitment to technological advancement and addressing unmet medical needs positions it as a pivotal player in the ongoing evolution of therapeutic treatment options.
“Lineage Cell Therapeutics Inc. trades at a P/E of -4.3 (undervalued) with modest ROE of -103.4%.”
Ask for details →Lineage Cell Therapeutics Inc. (ticker: LCTX) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 70 employees. Market cap is $276M.
The current price is $1.2 with a P/E ratio of -4.35x and P/B of 6.2x.
ROE is -103.36% and operating margin is -149.62%. Annual revenue is $15M.